Allogeneic adipose derived mesenchymal stem cells(Mayo Clinic)(Allogeneic adipose derived mesenchymal stem cells(Mayo Clinic))

概要

基本信息

药物类型

间充质干细胞疗法

别名-

靶点-

作用方式-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

Mayo Clinic

在研机构-

非在研机构-

权益机构-

最高研发阶段-

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

1

项与 Allogeneic adipose derived mesenchymal stem cells(Mayo Clinic) 相关的临床试验

NCT04388761

/ Withdrawn临床1期IIT

Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)

The purpose of this research is to test an investigational drug called Adipose Mesenchymal Stem Cells (aMSCs) for the treatment of ischemia re-perfusion injury (IRI) in patients that have had a kidney transplant.

开始日期2020-09-01

申办/合作机构

Mayo Clinic

100 项与 Allogeneic adipose derived mesenchymal stem cells(Mayo Clinic) 相关的临床结果

登录后查看更多信息

100 项与 Allogeneic adipose derived mesenchymal stem cells(Mayo Clinic) 相关的转化医学

登录后查看更多信息

100 项与 Allogeneic adipose derived mesenchymal stem cells(Mayo Clinic) 相关的专利（医药）

登录后查看更多信息

100 项与 Allogeneic adipose derived mesenchymal stem cells(Mayo Clinic) 相关的药物交易

登录后查看更多信息